Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed fingolimod in acute demyelinating optic neuritis
2012-002968-27Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fingolimod in demyelinating optic neuritis (ON) (2 arms), sponsored by Novartis. Primary endpoints: Retinal nerve fiber layer thinning and Axonal loss of retinal neurons. Started Nov 2012; status: terminated.
02
Drugs
fingolimod
03
Conditions
demyelinating optic neuritis (ON)
Beyond the preview
Go deeper on 2012-002968-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002968-27.